Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.640
+0.310 (7.16%)
At close: May 12, 2025, 4:00 PM
4.610
-0.030 (-0.65%)
After-hours: May 12, 2025, 7:56 PM EDT
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 800 employees as of December 31, 2024. The number of employees increased by 300 or 60.00% compared to the previous year.
Employees
800
Change (1Y)
300
Growth (1Y)
60.00%
Revenue / Employee
$74,738
Profits / Employee
-$718,469
Market Cap
1.89B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RXRX News
- 6 days ago - Recursion to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 days ago - Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Recursion Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 days ago - Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings - Seeking Alpha
- 8 days ago - Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden - GlobeNewsWire
- 14 days ago - Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th - GlobeNewsWire
- 20 days ago - Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 - GlobeNewsWire
- 26 days ago - HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data - PRNewsWire